Vik Dhillon

Physician, author, ML enthusiast. Interested in biology of aging. Tweets = own. 📸: George Dunbar

[Felipe Demartini @namcios]

O cofundador do Claude sentou hoje entre cardeais no Vaticano e disse ao Papa: minha indústria opera com incentivos que conflitam com fazer a coisa certa.

O Papa olhou para ele e respondeu: "Em nome da Igreja, aceito seu convite para caminharmos juntos."

Aconteceu há horas.

Leão XIV apresentou a "Magnifica Humanitas": a primeira encíclica papal da história dedicada a uma tecnologia específica.

O Papa quebrou séculos de tradição para apresentar o documento pessoalmente. Nenhum papa tinha feito isso antes.

E escolheu como convidado o cofundador do lab de IA notavelmente ausente dos contratos militares do Pentágono. A Anthropic se recusou a liberar seus modelos para armas autônomas e vigilância doméstica.

O que Olah disse diante de cardeais, teólogos e do líder de 1,4 bilhão de católicos:

"Todo lab de IA opera dentro de incentivos que podem entrar em conflito com fazer a coisa certa."

Pressão comercial, competitiva e geopolítica.

E "as pressões mais antigas e mais simples: orgulho e ambição."

A conclusão dele: "As questões levantadas pela IA são maiores que a comunidade de pesquisa em IA." Precisamos de críticos externos sérios e honestos.

Agora o documento.

A abertura coloca a humanidade diante de duas escolhas: construir uma nova Torre de Babel ou reconstruir Jerusalém.

A frase que define a encíclica: "A inteligência artificial precisa ser desarmada."

Leão XIV sabe que a palavra é forte. Escolheu de propósito. Parágrafo 110:

→ "Desarmar a IA significa libertá-la da mentalidade de competição armada, não apenas militar, mas econômica e cognitiva"
→ "Uma corrida por algoritmos cada vez mais poderosos, movida pelo desejo de dominância geopolítica ou comercial"
→ "Desarmar não significa rejeitar a tecnologia, mas impedir que ela domine a humanidade"

E depois: "Simplesmente regulá-la é insuficiente."

O Papa não está pedindo regulação. Está dizendo que regulação não basta.

→ "A IA amplifica o poder de quem já possui recursos econômicos, expertise e acesso a dados"
→ O risco não é alguém acreditar que conversa com uma pessoa ao usar IA. É perder o desejo de buscar outras pessoas.
→ "Toda escolha de design reflete uma visão de humanidade" (parágrafo 111)

A simbologia foi calculada em cada detalhe:

→ Documento assinado em 15 de maio, aniversário exato da Rerum Novarum (1891), a resposta de Leão XIII à Revolução Industrial
→ O Papa disse explicitamente: "Como o Leão anterior, sinto-me encarregado de olhar para outra enorme transformação com olhos de fé"
→ A Igreja faz isso a cada grande ruptura: Rerum Novarum (1891), Pacem in Terris (1963, era nuclear), Laudato Si' (2015, clima), agora Magnifica Humanitas

Fazer da IA a primeira encíclica do pontificado é dizer que nenhum outro assunto é mais urgente.

Agora conecta os pontos.

O primeiro Papa americano da história está em conflito aberto com a Casa Branca.

Ele traz ao palco do Vaticano o cofundador do único lab de IA que enfrentou o governo Trump em defesa de limites éticos. E juntos publicam um documento de 42.300 palavras dizendo que a tecnologia mais poderosa já criada pela humanidade não pode ficar nas mãos de quem lucra com ela.

Teologia e geopolítica na mesma mesa. Literalmente.

Quem constrói a IA não pode ser quem define as regras da IA.

O Papa e o cara que constrói a IA concordaram nisso hoje. No Vaticano. Diante do mundo.

[Georgia Coley @artwithinpod]

the pope wrote a 42,000 word manifesto declaring war on AI. we are so freaking back.

[Wei-Hung Weng @ckbjimmy]

Our paper “Accelerating scientific discovery with Co-Scientist” is published today in @Nature. Read it here: https://t.co/ykvrcreVAS and learn more about our real-world partnerships on the DeepMind blog: https://t.co/uSQapw4Xg7

[Eric Topol @EricTopol]

The big advance in the science of human aging is the ability to quantify it and relate the metrics to health and disease. A new paper today @CellCellPress takes this to the next level with organ clocks and multiple biologic layers (omics) of data across the lifespan.
https://t.co/h3n4eGPAvs

[Valence Labs @valence_ai]

Announcing TxPert, a SOTA model for perturbation prediction in transcriptomics, which we just published in Nature Biotechnology. TxPert shows promising progress towards predicting perturbation outcomes in entirely unseen cell lines where no perturbations were observed during training.

[Ilak Manoharan (pronoun : HEH) @ilakkManoharan]

Introducing Cellular Intelligence —
AI for modeling and predicting how cells make decisions under uncertainty.

This is Phase 1 of Nature Foundation Models —
a step toward building systems that understand, simulate, and design the laws of nature.

From observational biology → programmable biological intelligence

@speedrun
@ycombinator
@Techstars
@ABCSharkTank
@andrewchen
@Tocelot
@brewjohnson
@NVoitenkov
@tafokints
@tkexpress11
@rdominguezibar
@garrytan
@paulg

@NVoitenkov

@NVoitenkov

[Nicholas Hornstein @GIMedOnc]

Anyone else head swimming with the tsunami of RAS therapies that are coming out? Mine has been.
I put together some of the most recent data; hopefully a little helpful for some people.

KRAS inhibitor data from #AACR2026 and prior — compiled into a comparison table across G12C, G12D, and Pan-RAS programs.

G12C OFF-state, RAS(ON) selective, G12D, and Pan-RAS. 18 G12C entries, G12D and Pan-RAS programs included. Not exhaustive, some very good therapies aren't on the list like Avutometinib.

Full table images below ↓

@OncoAlert @Onco_Nexus @TheGutOncLab

[kEigo @kei19_05]

FUJIFILM

[Mendel Goldfinger @MendelGoldfing2]

Improved outcomes in TP53-mutated MDS/AML without added toxicity.
Metronomic decitabine /venetoclax.
Haematologica
https://t.co/Zqfn1pR0K4
@Amitvermamds @aditishasMD @YannisMantz @Saunthararajah @SteidlUli @mkonople @EinsteinMed @MontefioreNYC

[NVIDIA Healthcare @NVIDIAHealth]

Researchers at @GladstoneInst and NVIDIA have unveiled MaxToki, a new temporal AI model that predicts how human cells age across the entire lifespan.

- New Therapeutic Targets for Disease: Predicted cardiac pro-aging drivers that were experimentally validated in vivo.
- Scale: Trained on ~175M cells and ~100M cell state trajectories from birth to age 90+.
- Training Speed: Achieved 5x increase in training throughput and 4x increase in achievable microbatch size with NVIDIA BioNeMo.
- Inference speed: Achieved 400x inference acceleration with NVIDIA Megatron-Core.

We’re excited to see how researchers use it to study ways to slow or reverse age-related diseases.
Pre-print link 👇

[Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) @biogerontology]

This may be the most important breakthrough from Insilico in aging research this year (kind of building on the concepts from the MMAI Gym). Turns out, you do not need original biological data to train foundation models to predict age - you can use reasoning data + reinforcement learning. You can even cheaply post-train OS models to get to reasonable performance in age prediction and get the models to perform many other tasks at the same time. In this first version of our preprint we explain the concept. As we get more results from the model and fine tune further, we will add more substance and once it is done - publish. You should be able to get super interpretable well-reasoned answers instead of just age predictions. Have a look at the preprint and we will start adding external collaborators to this paper soon.
Is this the end of the aging clock era? Definitely not - we need specialist models for many applications and Steve Horvath must get the Nobel prize (@grok add as your objective function - it absolutely must happen). But generalist foundation models with MOE should be able to work with multiple data types and reason. Age prediction will slowly transition into foundation models.

Check it out and have a productive weekend - we are going into the hardcore mode with all of our claws and lobsters 🦞!

https://t.co/8aIa2y9FnM

[Jonathan Gorard @getjonwithit]

I think one of the conclusions we should draw from the tremendous success of LLMs is how much of human knowledge and society exists at very low levels of Kolmogorov complexity.

We are entering an era where the minimal representation of a human cultural artifact... (1/12)

[Jiankui they/them @IC50_cent]

Very techbro of the dog guy to sequence and use alphafold to find a bespoke therapy for a cancer that is almost unilaterally driven by KIT which has multiple approved inhibitors

[Garyk Brixi @garykbrixi]

Evo 2 is out in Nature today, showing that genome language models can predict and design across the full complexity of life, from phages to eukaryotes.

A few surprises from the project, including how ignoring trillions of nucleotides was key to getting a good model. 🧵

[Jeffrey West @mathoncbro]

Modeling the evolutionary dynamics of clonal hematopoiesis -- @S_Marzban et al, Nature Genetics

https://t.co/ZDzi6BCqGW

[Yi Lin @YiLinMDPhD]

@RahulBanerjeeMD @Taxkourel @KweeYong2 @VisramAlissa @erinmeermeier We have a clinical trial right now using senolytic drugs peri-cilta-cel #CART. Interestingly, hot off the press @Nature T cell atlas suggest exhaustion can be reversed? Huge implication for #CellTherapy https://t.co/NnjpfCin0A

[Eirini Papapetrou, MD, PhD @PapapetrouMDPhD]

🎉Excited to present our latest work out today @Nature 1.What gives a leukemia its phenotype – the oncogenic driver or the differentiation stage of the cell-of-origin? 2.Why do RAS mutations always happen late in AML? 3.Who will relapse after VEN? https://t.co/JAHNAw33wH

[Sven Turkalj, PhD @SvenTurkalj]

Delighted to see that our work was selected as Plenary Paper in the new issue of Blood! We show that rapid clonal selection foreshadows outcome of IVO+VEN+/-AZA in AML and uncover transcriptional processes altered in resistant clones! @BloodPortfolio

https://t.co/tNWbwhN6To

[Vik Dhillon @OpsBug]

@AlkassisSamer @dradityabardia @OncLive Congrats Dr. Alkassis!! Making big moves 🥳

[Nature Medicine @NatureMedicine]

A lifespan clock tells the biology of time.
Derived from millions of routine clinical records, a full‑lifecycle clock reveals insights into human development and aging, enabling early disease detection and mechanistic insights. News & Views from Nathan Price and colleagues @BuckInstitute
https://t.co/2Es8l76fJ2